Libor Havlı́ček

3.1k citations
57 papers · 2.7k indexed · 2 hit papers · h-index 24
Topics
Cancer-related Molecular Pathways (23 papers)Cancer Mechanisms and Therapy (8 papers)Biochemical and Molecular Research (7 papers)

In The Last Decade

Libor Havlı́ček

55 papers receiving 2.6k citations

Hit Papers

Inhibition of Cyclin‐Dependent Kinases by Purine Analogues199420262004201519971994200400600

Peers

Libor Havlı́ček
Comparison fields: 5 of 99
  • Molecular Biology 1.5k
  • Oncology 944
  • Organic Chemistry 602
  • Cell Biology 437
  • Plant Science 374
Replace Sophie Leclerc with:
Sophie Leclerc France
Joachim Gullbo Sweden
Sanjeev Shangary United States
Peter L. Toogood United States
Chung-Wai Shiau Taiwan
Jonathan M. Elkins United Kingdom
A. Chaikuad Germany
Stefania Sarno Italy
Gregory D. Vite United States
Akihiro Tomida Japan
Libor Havlı́ček relative to Sophie Leclerc France Sophie Leclerc's profile →
Citations per field
00.5×1.5×1.9×
Sophie Leclerc · 1×
Citations per year

Countries citing papers authored by Libor Havlı́ček

Since Specialization
Citations

This map shows the geographic impact of Libor Havlı́ček's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Havlı́ček with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Havlı́ček more than expected).

Fields of papers citing papers by Libor Havlı́ček

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Libor Havlı́ček. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Havlı́ček. The network helps show where Libor Havlı́ček may publish in the future.

Co-authorship network of co-authors of Libor Havlı́ček

This figure shows the co-authorship network connecting the top 25 collaborators of Libor Havlı́ček. A scholar is included among the top collaborators of Libor Havlı́ček based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Libor Havlı́ček. Libor Havlı́ček is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 10
3 7
4 25
5 7
6 30
7 21
8 31
9 10
10 23
11 11
12 34
13 66
14 47
15 23
16 24
17 47
18 4
19
Metabolism of olomoucine, roscovitine, and bohemine in small laboratory rodents
1
20
Inhibition of Cyclin‐Dependent Kinases by Purine Analoguesbreakdown →
562

About Libor Havlı́ček

Libor Havlı́ček is a scholar working on Oncology, Pharmacology and Toxicology, having authored 57 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (23 papers), Cancer Mechanisms and Therapy (8 papers) and Biochemical and Molecular Research (7 papers). The work is most often cited by research in Oncology (944 citations), Cell Biology (437 citations) and Molecular Biology (1.5k citations). Libor Havlı́ček has collaborated with scholars based in Czechia, France and United Kingdom. Frequent co-authors include Miroslav Strnad, Sophie Leclerc, Laurent Meijer, Walter Filgueira de Azevedo, Jaroslav Veselý, Vladimı́r Kryštof, Jun‐ya Kato, J. Julian Blow, Arianna Donella‐Deana and Lénaı̈ck Détivaud. Their work appears in journals such as PLoS ONE, Journal of Bacteriology and Chemosphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026